FRX vs. CRON, TEV, ABT, TLRY, NOT, PYR, SLS, NVO, DNA, and VBV
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Cronos Group (CRON), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Tilray Brands (TLRY), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Solaris Resources (SLS), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), and VBI Vaccines (VBV). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs.
Fennec Pharmaceuticals (TSE:FRX) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
Fennec Pharmaceuticals received 35 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
52.8% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.0% of Cronos Group shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Fennec Pharmaceuticals and 0 mentions for Cronos Group. Fennec Pharmaceuticals' average media sentiment score of 0.67 beat Cronos Group's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
Cronos Group has a consensus target price of C$3.54, indicating a potential upside of 35.63%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals.
Fennec Pharmaceuticals has a net margin of -2.30% compared to Cronos Group's net margin of -42.65%. Fennec Pharmaceuticals' return on equity of 29.94% beat Cronos Group's return on equity.
Fennec Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Summary
Fennec Pharmaceuticals beats Cronos Group on 12 of the 18 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy FRX Stock Free FRX Stock Alerts